Transition of Anti-pertussis Antibodies and the Safety of Japanese Diphteria-acellular Pertussis-Tetanus Vaccine administered in reduced doses among Adults
Not Applicable
- Conditions
- pertussis
- Registration Number
- JPRN-UMIN000010779
- Lead Sponsor
- ational Hospital Organization Saitama National Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
The person who is infected a malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method increased anti-pertussis antibodies titer after vaccination
- Secondary Outcome Measures
Name Time Method relative frequency of side effects after vaccination
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Japanese DTP vaccine in inducing anti-pertussis antibody transition in adults?
How does reduced-dose DTP vaccine compare to standard acellular pertussis vaccines in adult immunogenicity and safety profiles?
Which biomarkers correlate with sustained anti-pertussis antibody titers after reduced-dose DTP vaccination in adults?
What adverse event management strategies are recommended for Japanese DTP vaccine in reduced dosing regimens?
Are there combination approaches or competitor vaccines showing improved adult pertussis immunity compared to reduced-dose DTP?